Predictive value of integrative epigenetic profiling in metastatic melanoma (MM) patients (p) treated with BRAF/MEK inhibitors (BMI) and chemotherapy (CT).

Authors:

Abstract
E20059 Background: The treatment of MM has evolved over the last four years to include novel treatments in addition to CT, requiring predictive markers of response. Treatment with BMI provides benefit in overall survival, although with early resistance development. The value of CT in these p is limited. Hence, the aim of this work is to perform an integrative epigenetic profiling as predictive tool of resistance to treatment in MM p treated, in one hand with BRAF/MEK inhibitors, and in the other hand, CT-based treatment. The final goal is obtain epigenetic biomarkers to optimize treatment selection and p's outcome. Additionally, we pretend to identify epigenetic biomarkers related to metastatic process. Methods: It was analyzed 35 paraffin-embebbed primary tumor tissue samples from 35 MM p, 20 of them had been treated with BMI and 15 with CT. Additionally, it was analyzed the paired metastasis tissue for a half of them to study the effect of epigenetics in metastatic process. Epigenetic screening was perf...